Semaglutide 7.2mg trial results: 20.7%

A higher dose of Novo Nordisk's semaglutide led to greater weight loss than the currently-approved dose level — sold as Wegovy — in adults with obesity. "We are very pleased to demonstrate 20.7% weight loss and to see that 33% of patients achieved more than 25% weight loss with semaglutide 7.2 mg, with a [comparable] safety and tolerability profile," remarked Martin Holst Lange, the company's executive vice president for development.

Source: https://www.novonordisk.com/news-and-media/news-and-ir-materials/news-details.html?id=915087